Developing Innovative High-Impact Therapeutic Solutions that Address Major Unmet Needs in Healthcare

Learn More

Orchestra BioMed is a Healthcare Innovation Company

Orchestra BioMed is a biomedical innovation company focused on developing high-impact therapeutic solutions to address significant unmet needs in cardiovascular health and other areas. We specialize in developing novel therapies that are:

  • Designed to fit current clinical treatment paradigms and leverage the established procedural techniques well-known to interventional physicians; and
  • Based on the use as well as convergence of advanced medical technology, biopharmaceuticals, biomaterials-based drug delivery, and intelligent bioelectronic therapeutic algorithms

Our business model is designed to advance promising therapeutic solutions through development and aims to leverage strategic partnerships with established global commercial leaders to optimize commercialization and profitability. The Orchestra BioMed team of industry leaders has proven expertise in every phase of medtech and biopharma product development. Our primary focus on cardiovascular disease reflects our goal to rapidly advance disruptive solutions that will improve the standard of care for millions of patients worldwide.

Product Pipeline Overview

Advancing a deep, multi-asset pipeline of high-impact therapeutic solutions built around two technology platforms.

Learn More

News & Events

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease

September 17, 2019

First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease

Follows Breakthrough Device designation for Virtue Sirolimus-Eluting Balloon in coronary in-stent restenosis granted in Q2 2019

Orchestra BioMed Receives CE Mark for BackBeat Cardiac Neuromodulation Therapy (CNT) for Hypertension

September 4, 2019

Late-breaking BackBeat CNT randomized, double-blind clinical results selected by Cardiovascular Research Foundation for presentation at TCT 2019

Read All News